248 related articles for article (PubMed ID: 36484988)
21. Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.
Herrera Comoglio R; Vidal Guitart X
Prim Care Diabetes; 2021 Apr; 15(2):323-331. PubMed ID: 33248925
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Volke V; Katus U; Johannson A; Toompere K; Heinla K; Rünkorg K; Uusküla A
BMC Endocr Disord; 2022 Oct; 22(1):251. PubMed ID: 36261824
[TBL] [Abstract][Full Text] [Related]
23. Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.
Weeda ER; Ward R; Gebregziabher M; Chandler O; Strychalski ML; Axon RN; Taber DJ
Prim Care Diabetes; 2023 Aug; 17(4):386-391. PubMed ID: 37121788
[TBL] [Abstract][Full Text] [Related]
24. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
Hougen I; Whitlock RH; Komenda P; Rigatto C; Clemens KK; Tangri N
BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34969692
[TBL] [Abstract][Full Text] [Related]
25. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
26. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
Jørgensen CH; Gislason GH; Andersson C; Ahlehoff O; Charlot M; Schramm TK; Vaag A; Abildstrøm SZ; Torp-Pedersen C; Hansen PR
Cardiovasc Diabetol; 2010 Sep; 9():54. PubMed ID: 20843380
[TBL] [Abstract][Full Text] [Related]
27. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
29. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Green JB; Everett BM; Ghosh A; Younes N; Krause-Steinrauf H; Barzilay J; Desouza C; Inzucchi SE; Pokharel Y; Schade D; Scrymgeour A; Tan MH; Utzschneider KM; Mudaliar S;
Circulation; 2024 Mar; 149(13):993-1003. PubMed ID: 38344820
[TBL] [Abstract][Full Text] [Related]
31. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
[TBL] [Abstract][Full Text] [Related]
32. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
33. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
34. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
35. Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.
Ebert T; Sattar N; Greig M; Lamina C; Froissart M; Eckardt KU; Floege J; Kronenberg F; Stenvinkel P; Wheeler DC; Fotheringham J
Am J Kidney Dis; 2024 Jan; 83(1):18-27. PubMed ID: 37657634
[TBL] [Abstract][Full Text] [Related]
36. Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
Roumie CL; Chipman J; Min JY; Hackstadt AJ; Hung AM; Greevy RA; Grijalva CG; Elasy T; Griffin MR
JAMA; 2019 Sep; 322(12):1167-1177. PubMed ID: 31536102
[TBL] [Abstract][Full Text] [Related]
37. Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea.
Baker MC; Sheth K; Liu Y; Lu D; Lu R; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233646. PubMed ID: 36939700
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
Park SH; Jeong HE; Oh IS; Hong SM; Yu SH; Lee CB; Shin JY
Diabetes Obes Metab; 2021 Jun; 23(6):1232-1241. PubMed ID: 33502058
[TBL] [Abstract][Full Text] [Related]
39. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
